Manali K. Kamdar

2 weeks ago | cgtlive.com | Manali K. Kamdar |Noah Stansfield

Bristol Myers Squibb's lisocabtagene maraleucel (liso-cel, marketed as Breyanzi) is a chimeric antigen receptor (CAR) T-cell therapy that is approved for several hematologic malignancy indications in the United States.

3 weeks ago | cgtlive.com | Manali K. Kamdar |Noah Stansfield

“I think this really calls for a concerted effort around making sure that this data is out there so that the regulatory bodies can review it and further optimize the requirement around the 4 week window and hopefully shorten it for our patients to less than at least 2 to 2.5 weeks so that we not only allow them to return home, but also make sure that the safety is not compromised.” Bristol Myers Squibb's lisocabtagene maraleucel (liso-cel, marketed as Breyanzi), an FDA-approved chimeric...

3 weeks ago | cgtlive.com | Manali K. Kamdar |Noah Stansfield

Immix Biopharma and its subsidiary Nexcella are currently conducting a phase 1b/2 clinical trial (NCT06097832; NEXICART-2) in the United States aimed at evaluating NXC-201, an investigational autologous BCMA-directed chimeric antigen receptor T-cell (CAR-T) therapy, for the treatment of relapsed/refractory (r/r) light chain (AL) amyloidosis.

3 weeks ago | cgtlive.com | Manali K. Kamdar |Noah Stansfield

Bristol Myers Squibb's lisocabtagene maraleucel (liso-cel, marketed as Breyanzi), a chimeric antigen receptor (CAR) T-cell therapy FDA-approved for several hematologic malignancy indications, has become a fixture of standard care in recent years. Although, the need to monitor for potentially serious adverse events, especially cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), can become a barrier to accessiblity for some patients.

Jan 16, 2025 | cgtlive.com | Manali K. Kamdar |Noah Stansfield

This is the third part of an interview with Manali Kamdar, MD. For the first part, click here. For the second part, click here.